MX338397B - Anticuerpos anti - cxcr5 humanizados, derivados de los mismos y su uso. - Google Patents
Anticuerpos anti - cxcr5 humanizados, derivados de los mismos y su uso.Info
- Publication number
- MX338397B MX338397B MX2013014465A MX2013014465A MX338397B MX 338397 B MX338397 B MX 338397B MX 2013014465 A MX2013014465 A MX 2013014465A MX 2013014465 A MX2013014465 A MX 2013014465A MX 338397 B MX338397 B MX 338397B
- Authority
- MX
- Mexico
- Prior art keywords
- derivatives
- cxcr5
- humanized anti
- cxcr5 antibodies
- antibodies
- Prior art date
Links
- 102100031658 C-X-C chemokine receptor type 5 Human genes 0.000 abstract 3
- 101000922405 Homo sapiens C-X-C chemokine receptor type 5 Proteins 0.000 abstract 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 2
- 201000010099 disease Diseases 0.000 abstract 1
- 208000035475 disorder Diseases 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/46—Hybrid immunoglobulins
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/46—Hybrid immunoglobulins
- C07K16/461—Igs containing Ig-regions, -domains or -residues form different species
- C07K16/462—Igs containing a variable region (Fv) from one specie and a constant region (Fc) from another
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
- G16B5/00—ICT specially adapted for modelling or simulations in systems biology, e.g. gene-regulatory networks, protein interaction networks or metabolic networks
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/522—CH1 domain
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/524—CH2 domain
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/526—CH3 domain
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/567—Framework region [FR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Physics & Mathematics (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Biotechnology (AREA)
- Theoretical Computer Science (AREA)
- Evolutionary Biology (AREA)
- Spectroscopy & Molecular Physics (AREA)
- Physiology (AREA)
- Bioinformatics & Computational Biology (AREA)
- Medical Informatics (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Rheumatology (AREA)
- Dermatology (AREA)
- Epidemiology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Ophthalmology & Optometry (AREA)
Abstract
La presente invención se refiere a un método para preparar un anticuerpo humanizado o fragmento del mismo, que comprende: (a) identificar una región variable humana homologa a una región variable de un anticuerpo no humano; (b) construir un modelo de homología de la región variable del anticuerpo no humano usando la región variable humana identifica en la etapa (a) y realizar simulaciones de dinámica molecular para obtener la trayectoria dinámica molecular de la región variable del anticuerpo no humano; (c) analizar la trayectoria dinámica molecular de la región variable del anticuerpo no humano y determinar las puntuaciones de flexibilidad de aminoácidos para identificar aminoácidos en la región variable del anticuerpo no humano que son flexibles y aminoácidos que flanquean el residuo flexible; (d) construir modelos de homología de líneas germinales de anticuerpo humano y realizar simulaciones de dinámica molecular para obtener las trayectorias dinámicas moleculares de la región variable de las líneas germinales del anticuerpo humano; (e) analizar las trayectorias dinámicas moleculares de la región variable de las líneas germinales del anticuerpo humano y determinar las puntuaciones de flexibilidad de aminoácidos para identificar aminoácidos en la región variable de las líneas germinales del anticuerpo humano que son flexibles y aminoácidos que flanquean el residuo flexible; (f) identificar la región variable humana de las líneas germinales del anticuerpo humano que muestra la trayectoria dinámica molecular más similar a la trayectoria dinámica molecular de la región variable del anticuerpo no humano e identificar las mutaciones de humanización comparando las puntuaciones de flexibilidad de los aminoácidos más flexibles de las etapas (c ) y (e); (g) reemplazar los aminoácidos identificados de la etapa (c) con los aminoácidos identificados de la etapa (f) para producir una región variable humanizada; (h) confirmar que la región variable humanizada de la etapa (g) se parece a un anticuerpo humano comparando la trayectoria dinámica molecular de la región variable de las líneas germinales del anticuerpo humano; e (i) construir de manera recombinante una región variable humanizada al unir la región variable humanizada de la etapa (g) con una secuencia humana para producir un anticuerpo humanizado o fragmento del mismo.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US96879207P | 2007-08-29 | 2007-08-29 | |
| PCT/US2008/074381 WO2009032661A1 (en) | 2007-08-29 | 2008-08-27 | Humanized anti-cxcr5 antibodies, derivatives thereof and their uses |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX338397B true MX338397B (es) | 2016-04-15 |
Family
ID=40429297
Family Applications (5)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2013014466A MX338474B (es) | 2007-08-29 | 2008-08-27 | Anticuerpos anti - cxcr5 humanizados, derivados de los mismos y su uso. |
| MX2010001975A MX2010001975A (es) | 2007-08-29 | 2008-08-27 | Anticuerpos anti-cxcr5 humanizados, derivados de los mismos y su uso. |
| MX2013005976A MX338395B (es) | 2007-08-29 | 2008-08-27 | Anticuerpos anti-cxcr5 humanizados, derivados de los mismos y su uso. |
| MX2013014465A MX338397B (es) | 2007-08-29 | 2008-08-27 | Anticuerpos anti - cxcr5 humanizados, derivados de los mismos y su uso. |
| MX2013014467A MX346172B (es) | 2007-08-29 | 2008-08-27 | Anticuerpos anti - cxcr5 humanizados, derivados de los mismos y su uso. |
Family Applications Before (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2013014466A MX338474B (es) | 2007-08-29 | 2008-08-27 | Anticuerpos anti - cxcr5 humanizados, derivados de los mismos y su uso. |
| MX2010001975A MX2010001975A (es) | 2007-08-29 | 2008-08-27 | Anticuerpos anti-cxcr5 humanizados, derivados de los mismos y su uso. |
| MX2013005976A MX338395B (es) | 2007-08-29 | 2008-08-27 | Anticuerpos anti-cxcr5 humanizados, derivados de los mismos y su uso. |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2013014467A MX346172B (es) | 2007-08-29 | 2008-08-27 | Anticuerpos anti - cxcr5 humanizados, derivados de los mismos y su uso. |
Country Status (44)
Families Citing this family (99)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20120263733A1 (en) * | 2002-11-15 | 2012-10-18 | Morehouse School Of Medicine | Anti-cxcl9, anti-cxcl10, anti-cxcl11, anti-cxcl13, anti-cxcr3 and anti-cxcr5 agents for inhibition of inflammation |
| BRPI0714871A2 (pt) | 2006-07-18 | 2013-05-07 | Sanofi-Aventis | anticorpo antagonista para o tratamento de cÂncer |
| CN104017079B (zh) | 2007-08-29 | 2017-01-04 | 塞诺菲-安万特股份有限公司 | 人源化的抗-cxcr5抗体、其衍生物及它们的应用 |
| CA2733782A1 (en) * | 2008-08-14 | 2010-02-18 | Merck Sharp & Dohme Corp. | Methods for purifying antibodies using protein a affinity chromatography |
| FR2945538B1 (fr) | 2009-05-12 | 2014-12-26 | Sanofi Aventis | Anticorps humanises specifiques de la forme protofibrillaire du peptide beta-amyloide. |
| TW201116297A (en) | 2009-10-02 | 2011-05-16 | Sanofi Aventis | Antibodies that specifically bind to the EphA2 receptor |
| KR101802261B1 (ko) * | 2009-11-30 | 2017-11-28 | 바이오테스트 아게 | 전신 홍반성 낭창을 치료하기 위한 인간화된 항-ｉｌ-10 항체 |
| EP2397495A1 (en) | 2010-06-21 | 2011-12-21 | Sanofi | Novel antagonist antibodies and their Fab fragments against GPVI and uses thereof |
| EP2402371A1 (en) | 2010-07-01 | 2012-01-04 | Sanofi | Novel antagonist antibodies and their Fab fragments against GPVI and uses thereof |
| AU2010331807B2 (en) | 2009-12-18 | 2016-08-04 | Sanofi | Novel antagonist antibodies and their Fab fragments against GPVI and uses thereof |
| EP2336188A1 (en) | 2009-12-18 | 2011-06-22 | Sanofi-Aventis | Novel antagonist antibodies and their Fab fragments against GPVI and uses thereof |
| FR2958936A1 (fr) | 2010-04-14 | 2011-10-21 | Sanofi Aventis | Proteine de fusion robo1-fc et son utilisation dans le traitement des tumeurs |
| WO2012010582A1 (en) | 2010-07-21 | 2012-01-26 | Roche Glycart Ag | Anti-cxcr5 antibodies and methods of use |
| UY33578A (es) | 2010-08-31 | 2012-03-30 | Sanofi Sa | PÉPTIDO O COMPLEJO PEPTÍDICO QUE SE UNE A INTEGRINA a(ALFA) Y MÉTODOS Y USOS QUE IMPLICAN A LOS MISMOS |
| UA112170C2 (uk) | 2010-12-10 | 2016-08-10 | Санофі | Протипухлинна комбінація, що містить антитіло, яке специфічно розпізнає cd38, і бортезоміб |
| CN103608680A (zh) * | 2010-12-14 | 2014-02-26 | 詹姆士·W·里拉尔德 | 抗cxcl13抗体和抗cxcr5抗体在恶性肿瘤的治疗或检测中的用途 |
| AR085302A1 (es) | 2011-02-24 | 2013-09-18 | Sanofi Sa | Metodo de produccion de anticuerpos sialilados |
| KR20200014441A (ko) | 2012-01-20 | 2020-02-10 | 젠자임 코포레이션 | 항cxcr3 항체 |
| US9592289B2 (en) | 2012-03-26 | 2017-03-14 | Sanofi | Stable IgG4 based binding agent formulations |
| PT2830658T (pt) * | 2012-03-26 | 2018-12-28 | Sanofi Sa | Formulações de agente de ligação igg4 estável |
| EP4527855A3 (en) | 2012-03-26 | 2025-06-11 | Sanofi | Stable igg4 based binding agent formulations |
| CN120441698A (zh) | 2012-03-28 | 2025-08-08 | 赛诺菲 | 缓激肽b1受体配体的抗体 |
| CN112807427A (zh) * | 2012-06-27 | 2021-05-18 | 吉安特科技公司 | 一种抗-cxcl10抗体在制备用于治疗受试者中的炎性疾病的用途 |
| HK1212625A1 (zh) * | 2012-06-27 | 2016-06-17 | 吉安特科技公司 | 用於炎性疾病的抗-cxcl9、抗-cxcl10、抗-cxcl11、抗-cxcl13、抗-cxcr3和抗-cxcr5试剂 |
| PT3199552T (pt) | 2012-11-20 | 2020-03-25 | Sanofi Sa | Anticorpos anti-ceacam5 e suas utilizações |
| US20150322152A1 (en) | 2012-11-30 | 2015-11-12 | Institut Pasteur | Use of anti-fcyri and/or anti-fcyriia antibodies for treating arthritis, inflammation, thrombocytopenia and allergic shock |
| US10342869B2 (en) | 2012-12-07 | 2019-07-09 | The Regents Of The University Of California | Compositions comprising anti-CD38 antibodies and lenalidomide |
| ES2871816T3 (es) | 2012-12-27 | 2021-11-02 | Sanofi Sa | Anticuerpos anti-LAMP1 y conjugados anticuerpo-fármaco, y usos de los mismos |
| KR102241868B1 (ko) | 2013-03-13 | 2021-04-20 | 사노피 | 항-cd38 항체 및 카르필조밉을 포함하는 조성물 |
| TWI612059B (zh) * | 2013-03-15 | 2018-01-21 | 美國禮來大藥廠 | 泛－ＥＬＲ<sup>＋</sup>ＣＸＣ趨化因子抗體 |
| BR112015027388A2 (pt) * | 2013-05-02 | 2017-08-29 | Ares Trading Sa | Anticorpo monoclonal ou porção do mesmo que se liga a cxcr5, seu método de produção e seu uso, polinucleotídeos, vetores de expressão, célula hospedeira, e composição farmacêutica |
| ES2902413T3 (es) * | 2013-06-24 | 2022-03-28 | Neximmune Inc | Composiciones y procedimientos de inmunoterapia |
| TW201734054A (zh) | 2013-08-13 | 2017-10-01 | 賽諾菲公司 | 胞漿素原活化素抑制劑-１（ｐａｉ-１）之抗體及其用途 |
| SG10201710013RA (en) | 2013-08-13 | 2018-01-30 | Sanofi Sa | Antibodies to plasminogen activator inhibitor-1 (pai-1) and uses thereof |
| CN106255410B (zh) * | 2014-03-21 | 2020-01-10 | 瑞泽恩制药公司 | 产生单结构域结合蛋白的非人动物 |
| CN107148281A (zh) * | 2014-08-22 | 2017-09-08 | 索伦托治疗有限公司 | 结合cxcr5的抗原结合蛋白 |
| EP3237003B1 (en) * | 2014-12-24 | 2021-08-11 | NexImmune, Inc | Nanoparticle compositions and methods for immunotherapy |
| TN2017000275A1 (en) | 2015-01-23 | 2018-10-19 | Sanofi Sa | Anti-cd3 antibodies, anti-cd123 antibodies and bispecific antibodies specifically binding to cd3 and/or cd123 |
| CA2990076A1 (en) | 2015-06-22 | 2016-12-29 | Bayer Pharma Aktiengesellschaft | Antibody drug conjugates (adcs) and antibody prodrug conjugates (apdcs) with enzymatically cleavable groups |
| PE20180452A1 (es) | 2015-06-23 | 2018-03-05 | Bayer Pharma AG | Conjugados homogeneos especificos de sitio con inhibidores de ksp |
| JP2019500011A (ja) | 2015-11-03 | 2019-01-10 | メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツングＭｅｒｃｋ Ｐａｔｅｎｔ Ｇｅｓｅｌｌｓｃｈａｆｔ ｍｉｔ ｂｅｓｃｈｒａｅｎｋｔｅｒ Ｈａｆｔｕｎｇ | 腫瘍選択性及び阻害性が増強された二重特異性抗体及びその使用 |
| CN110498851B (zh) * | 2015-11-10 | 2022-10-11 | 孙嘉琳 | 一种抗肿瘤蛋白内皮抑素的衍生物及应用 |
| GB201604458D0 (en) | 2016-03-16 | 2016-04-27 | Immatics Biotechnologies Gmbh | Peptides and combination of peptides for use in immunotherapy against cancers |
| CN116059390A (zh) | 2016-03-24 | 2023-05-05 | 拜耳制药股份公司 | 具有酶促可裂解基团的细胞毒性活性物质的前药 |
| EP3919518A1 (en) | 2016-06-15 | 2021-12-08 | Bayer Pharma Aktiengesellschaft | Specific antibody-drug-conjugates (adcs) with ksp inhibitors and anti-cd123-antibodies |
| KR20220137159A (ko) * | 2016-07-05 | 2022-10-11 | 사노피 | 항체 제형 |
| TWI760345B (zh) | 2016-07-05 | 2022-04-11 | 法商賽諾菲公司 | 抗體調配物 |
| TWI790206B (zh) | 2016-07-18 | 2023-01-21 | 法商賽諾菲公司 | 特異性結合至ｃｄ３和ｃｄ１２３的雙特異性抗體樣結合蛋白 |
| JP7144051B2 (ja) * | 2016-09-26 | 2022-09-29 | Ｍｐｏ株式会社 | 卵子、受精卵又は胚の質改善剤 |
| RU2761390C2 (ru) | 2016-12-21 | 2021-12-07 | Байер Фарма Акциенгезельшафт | Конъюгаты связующего и активного вещества (adc), имеющие ферментативно расщепляемые группы |
| CN110072556B (zh) | 2016-12-21 | 2023-05-02 | 拜耳制药股份公司 | 具有ksp抑制剂的特异性抗体药物缀合物(adc) |
| US12059472B2 (en) | 2016-12-21 | 2024-08-13 | Bayer Aktiengesellschaft | Prodrugs of cytotoxic active agents having enzymatically cleavable groups |
| US20180244787A1 (en) | 2016-12-22 | 2018-08-30 | Sanofi | Anti-human cxcr3 antibodies for treatment of vitiligo |
| JP2020504744A (ja) | 2016-12-22 | 2020-02-13 | サノフイＳａｎｏｆｉ | 枯渇活性を有するヒト化ｃｘｃｒ３抗体およびその使用方法 |
| EP3354278A1 (en) | 2017-01-31 | 2018-08-01 | Sanofi | Neuronal cell protective effect of antibodies specific for the protofibrillar form of the beta-amyloid peptide |
| TWI808963B (zh) | 2017-03-22 | 2023-07-21 | 法商賽諾菲公司 | 使用人類化抗ｃｘｃｒ５抗體治療狼瘡 |
| KR20250052493A (ko) * | 2017-03-22 | 2025-04-18 | 사노피 | 인간화된 항-cxcr5 항체를 사용하는 루푸스의 치료 |
| WO2018218068A1 (en) * | 2017-05-24 | 2018-11-29 | Development Center For Biotechnology | Humanized antibodies against globo h and uses thereof in cancer treatments |
| CN110831978A (zh) | 2017-06-30 | 2020-02-21 | 酵活有限公司 | 稳定的嵌合fab |
| WO2019038368A1 (en) * | 2017-08-23 | 2019-02-28 | Max-Delbrück-Centrum Für Molekulare Medizin In Der Helmholtz-Gemeinschaft | CHIMERIC ANTIGEN RECEPTOR AND CAR CXCR5 BINDING T CARRIER |
| MX2020005662A (es) * | 2017-12-01 | 2020-08-20 | Pfizer | Anticuerpos anti-cxcr5 y composiciones y usos de los mismos. |
| EP3746079A1 (en) | 2018-01-31 | 2020-12-09 | Bayer Aktiengesellschaft | Antibody drug conjugates (adcs) with nampt inhibitors |
| US12331114B2 (en) * | 2018-02-13 | 2025-06-17 | Indian Institute Of Technology Bombay | Humanized anti-CD19 chimeric antigen receptor, its nucleic acid sequence and its preparation |
| WO2019190990A1 (en) * | 2018-03-26 | 2019-10-03 | Regeneron Pharmaceuticals, Inc. | Humanized rodents for testing therapeutic agents |
| CA3103327A1 (en) * | 2018-06-18 | 2019-12-26 | Bayer Aktiengesellschaft | Binder/active agent conjugates directed against cxcr5, having enzymatically cleavable linkers and improved activity profile |
| EP3753954A1 (en) | 2019-06-21 | 2020-12-23 | Université de Franche-Comté | Anti-cd123 antibodies, anti-cd123 chimeric antigen receptors and anti-cd123 chimeric antigen receptors t cells |
| US20210032370A1 (en) | 2019-08-02 | 2021-02-04 | Immatics Biotechnologies Gmbh | Recruiting agent further binding an mhc molecule |
| DE102019121007A1 (de) | 2019-08-02 | 2021-02-04 | Immatics Biotechnologies Gmbh | Antigenbindende Proteine, die spezifisch an MAGE-A binden |
| US20230132241A1 (en) | 2020-01-15 | 2023-04-27 | Immatics Biotechnologies Gmbh | Antigen binding proteins specifically binding prame |
| CN115515643A (zh) | 2020-02-28 | 2022-12-23 | 建新公司 | 用于优化的药物缀合的经修饰的结合多肽 |
| WO2023010483A1 (en) * | 2021-08-05 | 2023-02-09 | Hifibio (Hk) Limited | Anti-human cxcr5 antibody and uses thereof |
| BR112022020592A2 (pt) | 2020-04-24 | 2022-11-29 | Sanofi Sa | Combinações antitumor contendo conjugados de anticorpo anti-ceacam5, trifluridina e tipiracila |
| KR20230005203A (ko) | 2020-04-24 | 2023-01-09 | 사노피 | 항-ceacam5 항체 접합체 및 folfox를 함유하는 항종양 조합 |
| CA3181000A1 (en) | 2020-04-24 | 2021-10-28 | Sanofi | Antitumor combinations containing anti-ceacam5 antibody conjugates and folfiri |
| TW202203981A (zh) | 2020-04-24 | 2022-02-01 | 法商賽諾菲公司 | 含有抗ｃｅａｃａｍ５抗體接合物及西妥昔單抗（ｃｅｔｕｘｉｍａｂ）的抗腫瘤組合 |
| MX2023002330A (es) | 2020-09-04 | 2023-03-21 | Merck Patent Gmbh | Anticuerpos anti molecula de adhesion celular 5 relacionada con el antigeno carcinoembrionario (ceacam5) y conjugados y usos de los mismos. |
| CN112521499B (zh) * | 2020-12-24 | 2022-10-25 | 四川大学 | 抗cxcl13抗体及其用途 |
| KR20230152032A (ko) | 2021-02-03 | 2023-11-02 | 모차르트 쎄라퓨틱스 인코포레이티드 | 결합제 및 이를 사용하는 방법 |
| KR20230154981A (ko) * | 2021-03-09 | 2023-11-09 | 하이파이바이오 (에이치케이) 리미티드 | 항-인간 cxcr5 항체 및 이의 용도 |
| WO2022241034A1 (en) * | 2021-05-12 | 2022-11-17 | BioLegend, Inc. | Anti-ccr8 antibodies, antigen-binding fragments thereof, and agents and compositions and methods for making and using the same |
| CN113278072B (zh) * | 2021-05-25 | 2023-06-20 | 河南凯普瑞生物技术有限公司 | 一种抗体的制备方法 |
| AU2022355388A1 (en) * | 2021-09-30 | 2024-03-14 | Betta Pharmaceuticals Co., Ltd | Bispecific antibody and application thereof |
| WO2023076876A1 (en) | 2021-10-26 | 2023-05-04 | Mozart Therapeutics, Inc. | Modulation of immune responses to viral vectors |
| EP4426736A1 (en) | 2021-11-05 | 2024-09-11 | Sanofi | Antitumor combinations containing anti-ceacam5 antibody-drug conjugates and anti-vegfr-2 antibodies |
| US20250186603A1 (en) | 2022-03-09 | 2025-06-12 | Merck Patent Gmbh | Anti-gd2 antibodies, immunoconjugates and therapeutic uses thereof |
| TW202346354A (zh) | 2022-03-09 | 2023-12-01 | 德商馬克專利公司 | 抗ceacam5抗體及其結合物及用途 |
| EP4514390A1 (en) | 2022-04-28 | 2025-03-05 | The United States of America, as represented by the Secretary, Department of Health and Human Services | Recombinant polypeptides comprising single-domain antibodies targeting herv-k subtype hml-2 |
| WO2024011077A2 (en) | 2022-07-04 | 2024-01-11 | The United States Of America, As Represented By The Secretary, Department Of Health And Human | Monoclonal antibodies directed to phosphorylated psd95 and uses thereof |
| EP4673181A1 (en) | 2023-03-01 | 2026-01-07 | Sanofi | Use of anti-ceacam5 immunoconjugates for treating neuroendocrine cancers expressing ceacam5 |
| EP4427763A1 (en) | 2023-03-06 | 2024-09-11 | Sanofi | Antitumor combinations containing anti-ceacam5 antibody-drug conjugates, anti-vegfr-2 antibodies and anti-pd1/pd-l1 antibodies |
| EP4684034A1 (en) | 2023-03-23 | 2026-01-28 | Sanofi | Ceacam5 mrna assay for patient selection in cancer therapy |
| WO2024251733A1 (en) | 2023-06-05 | 2024-12-12 | Sanofi | Antitumor combinations containing anti-ceacam5 antibody-drug conjugates, anti-pd1/pd-l1 antibodies and anti-ctla4 antibodies |
| AU2024300235A1 (en) | 2023-07-27 | 2026-01-08 | Immatics Biotechnologies Gmbh | Antigen binding proteins against mageb2 |
| WO2025021979A1 (en) | 2023-07-27 | 2025-01-30 | Immatics Biotechnologies Gmbh | Novel t cell receptors targeting melanoma-associated antigen (mage) b2 and immune therapy using the same |
| CN117004700A (zh) * | 2023-10-07 | 2023-11-07 | 北京爱博生生物技术有限公司 | 单克隆抗体可变区基因高通量测序的方法及其所用组合物与试剂盒 |
| WO2025172525A1 (en) | 2024-02-15 | 2025-08-21 | Merck Patent Gmbh | Anti-gd2 antibodies and immunoconjugates for the treatment of gd2 positive cancer |
| WO2025210264A1 (en) | 2024-04-04 | 2025-10-09 | Merck Patent Gmbh | Antibody-drug-conjugates binding napi2b |
| WO2025242845A1 (en) | 2024-05-22 | 2025-11-27 | Merck Patent Gmbh | Colorectal cancer treatment |
| WO2026025031A1 (en) | 2024-07-26 | 2026-01-29 | Modernatx, Inc. | Mrna encoding mageb2 tcer molecule |
Family Cites Families (118)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3773919A (en) | 1969-10-23 | 1973-11-20 | Du Pont | Polylactide-drug mixtures |
| US4179337A (en) | 1973-07-20 | 1979-12-18 | Davis Frank F | Non-immunogenic polypeptides |
| US4307016A (en) | 1978-03-24 | 1981-12-22 | Takeda Chemical Industries, Ltd. | Demethyl maytansinoids |
| US4275149A (en) | 1978-11-24 | 1981-06-23 | Syva Company | Macromolecular environment control in specific receptor assays |
| US4318980A (en) | 1978-04-10 | 1982-03-09 | Miles Laboratories, Inc. | Heterogenous specific binding assay employing a cycling reactant as label |
| US4256746A (en) | 1978-11-14 | 1981-03-17 | Takeda Chemical Industries | Dechloromaytansinoids, their pharmaceutical compositions and method of use |
| JPS55102583A (en) | 1979-01-31 | 1980-08-05 | Takeda Chem Ind Ltd | 20-acyloxy-20-demethylmaytansinoid compound |
| JPS55162791A (en) | 1979-06-05 | 1980-12-18 | Takeda Chem Ind Ltd | Antibiotic c-15003pnd and its preparation |
| JPS6023084B2 (ja) | 1979-07-11 | 1985-06-05 | 味の素株式会社 | 代用血液 |
| JPS5645483A (en) | 1979-09-19 | 1981-04-25 | Takeda Chem Ind Ltd | C-15003phm and its preparation |
| EP0028683A1 (en) | 1979-09-21 | 1981-05-20 | Takeda Chemical Industries, Ltd. | Antibiotic C-15003 PHO and production thereof |
| JPS5645485A (en) | 1979-09-21 | 1981-04-25 | Takeda Chem Ind Ltd | Production of c-15003pnd |
| US4444887A (en) | 1979-12-10 | 1984-04-24 | Sloan-Kettering Institute | Process for making human antibody producing B-lymphocytes |
| US4376110A (en) | 1980-08-04 | 1983-03-08 | Hybritech, Incorporated | Immunometric assays using monoclonal antibodies |
| WO1982001188A1 (en) | 1980-10-08 | 1982-04-15 | Takeda Chemical Industries Ltd | 4,5-deoxymaytansinoide compounds and process for preparing same |
| US4450254A (en) | 1980-11-03 | 1984-05-22 | Standard Oil Company | Impact improvement of high nitrile resins |
| US4313946A (en) | 1981-01-27 | 1982-02-02 | The United States Of America As Represented By The Secretary Of Agriculture | Chemotherapeutically active maytansinoids from Trewia nudiflora |
| US4315929A (en) | 1981-01-27 | 1982-02-16 | The United States Of America As Represented By The Secretary Of Agriculture | Method of controlling the European corn borer with trewiasine |
| JPS57192389A (en) | 1981-05-20 | 1982-11-26 | Takeda Chem Ind Ltd | Novel maytansinoid |
| US4640835A (en) | 1981-10-30 | 1987-02-03 | Nippon Chemiphar Company, Ltd. | Plasminogen activator derivatives |
| US4716111A (en) | 1982-08-11 | 1987-12-29 | Trustees Of Boston University | Process for producing human antibodies |
| US4560655A (en) | 1982-12-16 | 1985-12-24 | Immunex Corporation | Serum-free cell culture medium and process for making same |
| US4657866A (en) | 1982-12-21 | 1987-04-14 | Sudhir Kumar | Serum-free, synthetic, completely chemically defined tissue culture media |
| GB8308235D0 (en) | 1983-03-25 | 1983-05-05 | Celltech Ltd | Polypeptides |
| US4767704A (en) | 1983-10-07 | 1988-08-30 | Columbia University In The City Of New York | Protein-free culture medium |
| US4496689A (en) | 1983-12-27 | 1985-01-29 | Miles Laboratories, Inc. | Covalently attached complex of alpha-1-proteinase inhibitor with a water soluble polymer |
| US5807715A (en) | 1984-08-27 | 1998-09-15 | The Board Of Trustees Of The Leland Stanford Junior University | Methods and transformed mammalian lymphocyte cells for producing functional antigen-binding protein including chimeric immunoglobulin |
| AU584417B2 (en) | 1985-04-01 | 1989-05-25 | Lonza Group Ag | Transformed myeloma cell-line and a process for the expression of a gene coding for a eukaryotic polypeptide employing same |
| US4737456A (en) | 1985-05-09 | 1988-04-12 | Syntex (U.S.A.) Inc. | Reducing interference in ligand-receptor binding assays |
| EP0206448B1 (en) | 1985-06-19 | 1990-11-14 | Ajinomoto Co., Inc. | Hemoglobin combined with a poly(alkylene oxide) |
| US4980286A (en) | 1985-07-05 | 1990-12-25 | Whitehead Institute For Biomedical Research | In vivo introduction and expression of foreign genetic material in epithelial cells |
| US4676980A (en) | 1985-09-23 | 1987-06-30 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Target specific cross-linked heteroantibodies |
| US5618920A (en) | 1985-11-01 | 1997-04-08 | Xoma Corporation | Modular assembly of antibody genes, antibodies prepared thereby and use |
| GB8601597D0 (en) | 1986-01-23 | 1986-02-26 | Wilson R H | Nucleotide sequences |
| WO1987005330A1 (en) | 1986-03-07 | 1987-09-11 | Michel Louis Eugene Bergh | Method for enhancing glycoprotein stability |
| US5225539A (en) | 1986-03-27 | 1993-07-06 | Medical Research Council | Recombinant altered antibodies and methods of making altered antibodies |
| GB8607679D0 (en) | 1986-03-27 | 1986-04-30 | Winter G P | Recombinant dna product |
| US4791192A (en) | 1986-06-26 | 1988-12-13 | Takeda Chemical Industries, Ltd. | Chemically modified protein with polyethyleneglycol |
| US4946778A (en) | 1987-09-21 | 1990-08-07 | Genex Corporation | Single polypeptide chain binding molecules |
| GB8717430D0 (en) | 1987-07-23 | 1987-08-26 | Celltech Ltd | Recombinant dna product |
| IL89489A0 (en) | 1988-03-09 | 1989-09-10 | Hybritech Inc | Chimeric antibodies directed against human carcinoembryonic antigen |
| AU631545B2 (en) | 1988-04-15 | 1992-12-03 | Protein Design Labs, Inc. | Il-2 receptor-specific chimeric antibodies |
| ATE119198T1 (de) | 1988-04-16 | 1995-03-15 | Celltech Ltd | Verfahren zur herstellung von proteinen mittels rekombinanter dna. |
| DE68921982T4 (de) | 1988-06-14 | 1996-04-25 | Cetus Oncology Corp | Kupplungsmittel und sterisch gehinderte, mit disulfid gebundene konjugate daraus. |
| US5223409A (en) | 1988-09-02 | 1993-06-29 | Protein Engineering Corp. | Directed evolution of novel binding proteins |
| US6048728A (en) | 1988-09-23 | 2000-04-11 | Chiron Corporation | Cell culture medium for enhanced cell growth, culture longevity, and product expression |
| US5534617A (en) | 1988-10-28 | 1996-07-09 | Genentech, Inc. | Human growth hormone variants having greater affinity for human growth hormone receptor at site 1 |
| DE68913658T3 (de) | 1988-11-11 | 2005-07-21 | Stratagene, La Jolla | Klonierung von Immunglobulin Sequenzen aus den variablen Domänen |
| US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| ZA902949B (en) | 1989-05-05 | 1992-02-26 | Res Dev Foundation | A novel antibody delivery system for biological response modifiers |
| CA2018228C (en) | 1989-06-05 | 1996-02-27 | Nancy L. Parenteau | Cell culture systems and media |
| US5413923A (en) | 1989-07-25 | 1995-05-09 | Cell Genesys, Inc. | Homologous recombination for universal donor cells and chimeric mammalian hosts |
| FR2650598B1 (fr) | 1989-08-03 | 1994-06-03 | Rhone Poulenc Sante | Derives de l'albumine a fonction therapeutique |
| US5436146A (en) | 1989-09-07 | 1995-07-25 | The Trustees Of Princeton University | Helper-free stocks of recombinant adeno-associated virus vectors |
| GB8928874D0 (en) | 1989-12-21 | 1990-02-28 | Celltech Ltd | Humanised antibodies |
| DK0710719T3 (da) | 1990-01-12 | 2007-07-09 | Amgen Fremont Inc | Frembringelse af xenogene antistoffer |
| US5314995A (en) | 1990-01-22 | 1994-05-24 | Oncogen | Therapeutic interleukin-2-antibody based fusion proteins |
| DE69127749T2 (de) | 1990-03-20 | 1998-04-16 | The Trustees Of Columbia University In The City Of New York, New York, N.Y. | Chimäre antikörper mit rezeptor-bindenden liganden anstelle ihrer konstanten region |
| GB9015198D0 (en) | 1990-07-10 | 1990-08-29 | Brien Caroline J O | Binding substance |
| US5661016A (en) | 1990-08-29 | 1997-08-26 | Genpharm International Inc. | Transgenic non-human animals capable of producing heterologous antibodies of various isotypes |
| US5814318A (en) | 1990-08-29 | 1998-09-29 | Genpharm International Inc. | Transgenic non-human animals for producing heterologous antibodies |
| US5633425A (en) | 1990-08-29 | 1997-05-27 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
| US5545806A (en) | 1990-08-29 | 1996-08-13 | Genpharm International, Inc. | Ransgenic non-human animals for producing heterologous antibodies |
| DE69127627T2 (de) | 1990-08-29 | 1998-02-19 | Genpharm Int | Produktion und Nützung nicht-menschliche transgentiere zur Produktion heterologe Antikörper |
| US5625126A (en) | 1990-08-29 | 1997-04-29 | Genpharm International, Inc. | Transgenic non-human animals for producing heterologous antibodies |
| CA2092323A1 (en) | 1990-10-01 | 1992-04-02 | George Y. Wu | Targeting viruses and cells for selective internalization by cells |
| US5122469A (en) | 1990-10-03 | 1992-06-16 | Genentech, Inc. | Method for culturing Chinese hamster ovary cells to improve production of recombinant proteins |
| AU660297B2 (en) | 1990-11-09 | 1995-06-22 | Stephen D. Gillies | Cytokine immunoconjugates |
| AU668870B2 (en) | 1991-05-14 | 1996-05-23 | Targetech, Inc | Targeted delivery of genes encoding immunogenic proteins |
| DE69233482T2 (de) | 1991-05-17 | 2006-01-12 | Merck & Co., Inc. | Verfahren zur Verminderung der Immunogenität der variablen Antikörperdomänen |
| CA2103371C (en) | 1991-06-05 | 2003-09-16 | George Y. Wu | Targeted delivery of genes encoding secretory proteins |
| WO1992022653A1 (en) | 1991-06-14 | 1992-12-23 | Genentech, Inc. | Method for making humanized antibodies |
| ES2136092T3 (es) | 1991-09-23 | 1999-11-16 | Medical Res Council | Procedimientos para la produccion de anticuerpos humanizados. |
| WO1993008829A1 (en) | 1991-11-04 | 1993-05-13 | The Regents Of The University Of California | Compositions that mediate killing of hiv-infected cells |
| ATE408012T1 (de) | 1991-12-02 | 2008-09-15 | Medical Res Council | Herstellung von autoantikörpern auf phagenoberflächen ausgehend von antikörpersegmentbibliotheken |
| US5869619A (en) | 1991-12-13 | 1999-02-09 | Xoma Corporation | Modified antibody variable domains |
| AU3434393A (en) | 1992-01-17 | 1993-08-03 | Regents Of The University Of Michigan, The | Targeted virus |
| FR2686901A1 (fr) | 1992-01-31 | 1993-08-06 | Rhone Poulenc Rorer Sa | Nouveaux polypeptides antithrombotiques, leur preparation et compositions pharmaceutiques les contenant. |
| FR2686899B1 (fr) | 1992-01-31 | 1995-09-01 | Rhone Poulenc Rorer Sa | Nouveaux polypeptides biologiquement actifs, leur preparation et compositions pharmaceutiques les contenant. |
| ATE503496T1 (de) | 1992-02-06 | 2011-04-15 | Novartis Vaccines & Diagnostic | Biosynthetisches bindeprotein für tumormarker |
| CA2076465C (en) | 1992-03-25 | 2002-11-26 | Ravi V. J. Chari | Cell binding agent conjugates of analogues and derivatives of cc-1065 |
| EP0633943A4 (en) | 1992-04-03 | 1997-05-02 | Alexander T Young | GENTHERAPY USING TARGETED VIRAL VECTORS. |
| AU4025193A (en) | 1992-04-08 | 1993-11-18 | Cetus Oncology Corporation | Humanized C-erbB-2 specific antibodies |
| ZA932522B (en) | 1992-04-10 | 1993-12-20 | Res Dev Foundation | Immunotoxins directed against c-erbB-2(HER/neu) related surface antigens |
| CA2141602A1 (en) | 1992-08-26 | 1994-03-03 | Philip Leder | Use of the cytokine ip-10 as an anti-tumor agent |
| US5639641A (en) | 1992-09-09 | 1997-06-17 | Immunogen Inc. | Resurfacing of rodent antibodies |
| KR950703640A (ko) | 1992-10-09 | 1995-09-20 | 가일 케이,나우톤. | 간 보존 세포(liver reserve cells) |
| EP0673431A1 (en) | 1992-12-03 | 1995-09-27 | Genzyme Corporation | Gene therapy for cystic fibrosis |
| US6838254B1 (en) | 1993-04-29 | 2005-01-04 | Conopco, Inc. | Production of antibodies or (functionalized) fragments thereof derived from heavy chain immunoglobulins of camelidae |
| US6165463A (en) | 1997-10-16 | 2000-12-26 | Inhale Therapeutic Systems, Inc. | Dispersible antibody compositions and methods for their preparation and use |
| EP1978033A3 (en) | 1995-04-27 | 2008-12-24 | Amgen Fremont Inc. | Human antibodies derived from immunized xenomice |
| WO1996034096A1 (en) | 1995-04-28 | 1996-10-31 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
| AU715543B2 (en) | 1995-09-08 | 2000-02-03 | Genzyme Corporation | Improved AAV vectors for gene therapy |
| AU5711196A (en) | 1996-03-14 | 1997-10-01 | Human Genome Sciences, Inc. | Apoptosis inducing molecule i |
| CA2249195A1 (en) | 1996-03-18 | 1997-09-25 | Board Of Regents, The University Of Texas System | Immunoglobin-like domains with increased half lives |
| KR20030096450A (ko) | 1996-03-22 | 2003-12-31 | 휴먼 게놈 사이언시즈, 인코포레이티드 | 고사 유도 분자 ⅱ |
| US5916771A (en) | 1996-10-11 | 1999-06-29 | Abgenix, Inc. | Production of a multimeric protein by cell fusion method |
| WO1998023289A1 (en) | 1996-11-27 | 1998-06-04 | The General Hospital Corporation | MODULATION OF IgG BINDING TO FcRn |
| ATE549918T1 (de) | 1996-12-03 | 2012-04-15 | Amgen Fremont Inc | Menschliche antikörper, die ausdrücklich menschliches tnf alpha binden |
| US6277375B1 (en) | 1997-03-03 | 2001-08-21 | Board Of Regents, The University Of Texas System | Immunoglobulin-like domains with increased half-lives |
| EP0970126B1 (en) | 1997-04-14 | 2001-04-18 | Micromet AG | Novel method for the production of antihuman antigen receptors and uses thereof |
| US6235883B1 (en) | 1997-05-05 | 2001-05-22 | Abgenix, Inc. | Human monoclonal antibodies to epidermal growth factor receptor |
| US6642051B1 (en) | 1997-10-21 | 2003-11-04 | Targeted Genetics Corporation | Amplifiable adeno-associated virus(AAV) packaging cassettes for the production of recombinant AAV vectors |
| WO1999023105A1 (en) | 1997-11-03 | 1999-05-14 | Human Genome Sciences, Inc. | Vegi, an inhibitor of angiogenesis and tumor growth |
| CA2361877A1 (en) | 1999-03-01 | 2000-09-08 | Genentech, Inc. | Antibodies for cancer therapy and diagnosis |
| EP1276856A4 (en) | 2000-04-12 | 2004-06-09 | Human Genome Sciences Inc | ALBUMIN FUSION PROTEINS |
| US6333410B1 (en) | 2000-08-18 | 2001-12-25 | Immunogen, Inc. | Process for the preparation and purification of thiol-containing maytansinoids |
| WO2002020615A2 (en) * | 2000-09-08 | 2002-03-14 | Micromet Ag | Antibody and/or chemokine constructs which bind to a chemokine receptor and their use in immunological disorders |
| US7321026B2 (en) | 2001-06-27 | 2008-01-22 | Skytech Technology Limited | Framework-patched immunoglobulins |
| RU2325387C2 (ru) * | 2001-12-21 | 2008-05-27 | Анормед Инк. | Гетероциклические соединения с повышенной эффективностью, связывающиеся с рецептором хемокина |
| US7470775B2 (en) * | 2002-06-07 | 2008-12-30 | The United States Of America As Represented By The Department Of Health And Human Services | Anti-CD30 stalk and anti-CD30 antibodies suitable for use in immunotoxins |
| WO2004015426A1 (en) * | 2002-08-06 | 2004-02-19 | Bayer Healthcare Ag | Diagnostics and therapeutics for diseases associated with human cxc chemokine receptor 5(cxcr5) |
| TW200530269A (en) * | 2003-12-12 | 2005-09-16 | Chugai Pharmaceutical Co Ltd | Anti-Mpl antibodies |
| NZ579482A (en) | 2004-06-01 | 2011-02-25 | Genentech Inc | Antibody drug conjugates and methods |
| US20060148009A1 (en) | 2004-10-12 | 2006-07-06 | Xencor, Inc. | Prediction and assessment of immunogenicity |
| GB0607774D0 (en) * | 2006-04-20 | 2006-05-31 | Renovo Group Plc | Medicaments |
| US20070266448A1 (en) * | 2006-05-11 | 2007-11-15 | Alexander Lifke | Method for the production of antibodies |
| CN104017079B (zh) | 2007-08-29 | 2017-01-04 | 塞诺菲-安万特股份有限公司 | 人源化的抗-cxcr5抗体、其衍生物及它们的应用 |
-
2008
- 2008-08-27 CN CN201410307453.9A patent/CN104017079B/zh active Active
- 2008-08-27 MX MX2013014466A patent/MX338474B/es unknown
- 2008-08-27 CN CN200880113572.3A patent/CN101842115B/zh active Active
- 2008-08-27 PA PA20088794201A patent/PA8794201A1/es unknown
- 2008-08-27 MX MX2010001975A patent/MX2010001975A/es active IP Right Grant
- 2008-08-27 AU AU2008296538A patent/AU2008296538B2/en active Active
- 2008-08-27 MX MX2013005976A patent/MX338395B/es unknown
- 2008-08-27 UY UY31309A patent/UY31309A1/es not_active Application Discontinuation
- 2008-08-27 KR KR1020147026311A patent/KR101667944B1/ko not_active Expired - Fee Related
- 2008-08-27 BR BRPI0815983A patent/BRPI0815983A2/pt not_active Application Discontinuation
- 2008-08-27 HR HRP20180873TT patent/HRP20180873T1/hr unknown
- 2008-08-27 UA UAA201312423A patent/UA117446C2/uk unknown
- 2008-08-27 KR KR1020157017528A patent/KR101701140B1/ko not_active Expired - Fee Related
- 2008-08-27 MX MX2013014465A patent/MX338397B/es unknown
- 2008-08-27 MX MX2013014467A patent/MX346172B/es unknown
- 2008-08-27 LT LTEP08798744.2T patent/LT2195023T/lt unknown
- 2008-08-27 RU RU2015147300A patent/RU2015147300A/ru not_active Application Discontinuation
- 2008-08-27 KR KR1020107006630A patent/KR101599704B1/ko not_active Expired - Fee Related
- 2008-08-27 WO PCT/US2008/074381 patent/WO2009032661A1/en not_active Ceased
- 2008-08-27 NO NO08798744A patent/NO2195023T3/no unknown
- 2008-08-27 CA CA2698203A patent/CA2698203C/en active Active
- 2008-08-27 SG SG10201407388XA patent/SG10201407388XA/en unknown
- 2008-08-27 MY MYPI2010000837A patent/MY159201A/en unknown
- 2008-08-27 EP EP08798744.2A patent/EP2195023B1/en active Active
- 2008-08-27 EP EP20191628.5A patent/EP3792284A1/en active Pending
- 2008-08-27 RS RS20180659A patent/RS57273B1/sr unknown
- 2008-08-27 DK DK08798744.2T patent/DK2195023T3/en active
- 2008-08-27 RU RU2010111751/10A patent/RU2571515C2/ru not_active IP Right Cessation
- 2008-08-27 EP EP18154804.1A patent/EP3354662B1/en active Active
- 2008-08-27 PL PL08798744T patent/PL2195023T3/pl unknown
- 2008-08-27 US US12/675,799 patent/US8647622B2/en active Active
- 2008-08-27 PE PE2008001444A patent/PE20090993A1/es not_active Application Discontinuation
- 2008-08-27 UA UAA201003491A patent/UA104715C2/uk unknown
- 2008-08-27 TR TR2018/07983T patent/TR201807983T4/tr unknown
- 2008-08-27 JP JP2010523100A patent/JP5743543B2/ja active Active
- 2008-08-27 PT PT87987442T patent/PT2195023T/pt unknown
- 2008-08-27 CN CN202010815880.3A patent/CN111909273B/zh active Active
- 2008-08-27 ES ES08798744.2T patent/ES2672769T3/es active Active
- 2008-08-27 SI SI200831964T patent/SI2195023T1/en unknown
- 2008-08-27 HU HUE08798744A patent/HUE037489T2/hu unknown
- 2008-08-27 CN CN201410307133.3A patent/CN104017078B/zh active Active
- 2008-08-27 NZ NZ583605A patent/NZ583605A/xx not_active IP Right Cessation
- 2008-08-27 KR KR1020147023916A patent/KR20140117638A/ko not_active Ceased
- 2008-08-29 TW TW105114943A patent/TWI608017B/zh not_active IP Right Cessation
- 2008-08-29 TW TW097133372A patent/TWI439468B/zh not_active IP Right Cessation
- 2008-08-29 TW TW106127131A patent/TW201741341A/zh unknown
- 2008-08-29 TW TW103111438A patent/TWI574976B/zh not_active IP Right Cessation
- 2008-08-29 AR ARP080103776A patent/AR068354A1/es not_active Application Discontinuation
- 2008-08-29 CL CL2008002565A patent/CL2008002565A1/es unknown
-
2010
- 2010-02-19 NI NI201000028A patent/NI201000028A/es unknown
- 2010-02-19 NI NI2010000281A patent/NI201000281A/es unknown
- 2010-02-23 CR CR11293A patent/CR11293A/es unknown
- 2010-02-23 TN TNP2010000092A patent/TN2010000092A1/fr unknown
- 2010-02-23 EC EC2010009985A patent/ECSP109985A/es unknown
- 2010-02-24 SV SV2010003494A patent/SV2010003494A/es unknown
- 2010-02-25 IL IL204173A patent/IL204173A/en active IP Right Grant
- 2010-02-26 DO DO2010000069A patent/DOP2010000069A/es unknown
- 2010-03-02 ZA ZA2010/01514A patent/ZA201001514B/en unknown
- 2010-03-08 MA MA32673A patent/MA31821B1/fr unknown
- 2010-04-05 CO CO10037770A patent/CO6270238A2/es active IP Right Grant
-
2013
- 2013-03-11 US US13/794,224 patent/US9228019B2/en active Active
- 2013-03-11 US US13/794,264 patent/US8980262B2/en active Active
- 2013-03-11 US US13/794,244 patent/US9243067B2/en active Active
- 2013-03-11 US US13/794,253 patent/US20130243793A1/en not_active Abandoned
- 2013-03-11 US US13/794,281 patent/US9175087B2/en active Active
-
2014
- 2014-12-26 JP JP2014263780A patent/JP6129152B2/ja active Active
-
2015
- 2015-02-05 CR CR20150054A patent/CR20150054A/es unknown
- 2015-02-05 PH PH12015500248A patent/PH12015500248A1/en unknown
- 2015-04-28 IL IL238505A patent/IL238505A/en active IP Right Grant
-
2016
- 2016-08-22 US US15/243,046 patent/US9815902B2/en active Active
-
2017
- 2017-03-06 JP JP2017041210A patent/JP2017123866A/ja active Pending
-
2018
- 2018-01-03 US US15/725,253 patent/US20180100019A1/en not_active Abandoned
- 2018-06-06 CY CY181100591T patent/CY1120665T1/el unknown
- 2018-07-20 AR ARP180102046 patent/AR112564A2/es unknown
-
2021
- 2021-08-20 US US17/407,651 patent/US20220073629A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PH12015500248A1 (en) | Humanized anti-cxcr5 antibodies, derivatives thereof and their uses | |
| MX2009004532A (es) | Composiciones y metodos para unir esfingosina-1-fosfato. | |
| AU2016219704A1 (en) | Anti-Notch1 antibodies | |
| MX2009008104A (es) | Hepcidina, antagonistas de hepcidina y metodos de uso. | |
| MY177564A (en) | Anti-nr10 antibody and use thereof | |
| MY155621A (en) | Axl antibodies | |
| MX2009013082A (es) | Anticuerpos contra c3b y metodos para la prevencion y el tratamiento de trastornos asociados con el complemento. | |
| UA100874C2 (en) | Bivalent bispecific antibodies | |
| MX2010006396A (es) | Anticuerpos bivalentes, biespecificos. | |
| MX2010005888A (es) | Anticuerpos bivalentes biespecificos. | |
| MX2010005682A (es) | Anticuerpos bivalentes, biespecificos. | |
| MX2009001110A (es) | Anticuerpos monoclonales anti-il-6 y usos de los mismos. | |
| WO2010032059A3 (en) | Antibodies directed to cd105 and uses thereof | |
| MY165273A (en) | Anti-cd48 antibodies and uses thereof | |
| PH12013500356A1 (en) | Engineered anti-tslp antibody | |
| MX2010004219A (es) | Agentes de enlace de cd19 y usos de los mismos. | |
| UA113397C2 (xx) | Попередження несприятливих ефектів, спричинених специфічними доменами зв'язування cd3 | |
| MX2009006891A (es) | Anticuerpos cd44. | |
| TN2010000213A1 (en) | Wise binding antibodies and epitopes | |
| MX2010003325A (es) | Anticuepos novedosos. | |
| TW200714290A (en) | Anti-M-CSF antibody compositions having reduced levels of endotoxin | |
| WO2008097439A3 (en) | Anti-autoimmune antibodies for treatment of pemphigus | |
| WO2008150530A3 (en) | Cripto binding molecules | |
| EA201101241A1 (ru) | Лечение лейкозов и хронических миелопролиферативных болезней антителами к ерна3 | |
| MY154715A (en) | Anti-nr10 antibody and use thereof |